Profil
Christina Furebring is currently the Deputy Director at Atlas Therapeutics AB and A Bioscience Incentive AB. She is also the Chief Operations Officer at Strike Pharma AB since 2022.
Previously, she worked as the Senior Vice President-Preclinical Development at Alligator Bioscience AB. Dr. Furebring holds a doctorate degree from the University of Lund.
Aktiva positioner av Christina Furebring
| Företag | Position | Start |
|---|---|---|
A Bioscience Incentive AB | Företagsledare/Principal | - |
Atlas Therapeutics AB
Atlas Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops and manufactures antibodies drugs | Företagsledare/Principal | - |
Strike Pharma AB
Strike Pharma AB Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that engages in development of immunotherapeutic treatments | Verksamhetschef | 2022-01-01 |
Tidigare kända positioner av Christina Furebring
| Företag | Position | Slut |
|---|---|---|
| ALLIGATOR BIOSCIENCE AB | Företagsledare/Principal | - |
Christina Furebrings utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 5 |
|---|---|
Alligator Bioscience AB
Alligator Bioscience AB BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops antibodies for the treatment of cancers | Health Technology |
University of Lund
University of Lund Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atlas Therapeutics AB
Atlas Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops and manufactures antibodies drugs | Health Technology |
A Bioscience Incentive AB | |
Strike Pharma AB
Strike Pharma AB Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that engages in development of immunotherapeutic treatments | Commercial Services |
















